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MicroRNAs (miRNAs) arepost-transcriptional regulatorsof geneexpressioncritical fororganismalviability.Changes
inmiRNAactivity are common in cancer, but howthese changes relate to subsequent alterations in transcription and
the process of tumorigenesis is not well understood. Here, we report a deep transcriptional, oncogenic network reg-
ulatedbymiRNAs.Wepresent analysis of thegeneexpressionandphenotypic changes associatedwith globalmiRNA
restoration inmiRNA-deficient fibroblasts. This analysis uncovers amiRNA-repressednetwork containing oncofetal
genes Imp1, Imp2, and Imp3 (Imp1–3) that is up-regulatedprimarily transcriptionally >100-folduponDicer loss and is
resistant to resilencing by complete restoration of miRNA activity. This Dicer-resistant epigenetic switch confers
tumorigenicity to these cells. Let-7 targets Imp1–3 are required for this tumorigenicity and feed back to reinforce
and sustain expression of the oncogenic network. Together, these Dicer-resistant genes constitute an mRNA ex-
pression signature that is present in numerous human cancers and is associated with poor survival.
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MicroRNAs (miRNAs) are an abundant class of non-
coding RNAs that repress gene expression typically ap-
proximately twofold through target degradation and/or
translational inhibition (Baek et al. 2008; Bartel 2009;
Ghildiyal and Zamore 2009). miRNAs regulate many
processes, including development (Bernstein et al. 2003;
Wienholds et al. 2003), differentiation (Kanellopoulou et
al. 2005; Xu et al. 2009), apoptosis (Cimmino et al. 2005;
Harfe et al. 2005), and proliferation (Wang et al. 2008).
Consistent with such broad influence, miRNA deregu-
lation is commonly observed in cancer, with both onco-
genic and tumor-suppressive roles having been reported
(Ventura and Jacks 2009; Lin and Gregory 2015). Let-7
miRNAs comprise a tumor suppressor family that is
down-regulated in multiple cancers and correlates in-
versely with patient survival (Calin 2004; Takamizawa
et al. 2004; Boyerinas et al. 2010; Nguyen et al. 2014; Ku-
gel et al. 2016; Manier et al. 2016; Powers et al. 2016). Un-
derlying the potent tumor suppressor activity of let-7 is
repression of well-established oncogenic mRNAs such
as Lin-28, Hmga2,Myc, Ras, and the Igf2 mRNA-binding
protein family Imp1, Imp2, and Imp3 (Imp1–3) (Johnson
et al. 2005; Lee and Dutta 2007; Sampson et al. 2007; Boy-
erinas et al. 2008).
Imp1–3 are an RNA-binding protein (RBP) family that
control RNA localization, stability, and translation (Bell
et al. 2013). Along with Hmga2 and Lin-28, Imp1–3 are
categorized as oncofetal genes, defined based on their
high expression during embryogenesis and re-expression
in diverse cancer types, where they collectively promote
stemness, proliferation, invasion, and metastasis (Boyeri-
nas et al. 2008; Janiszewska et al. 2012; Gurtan et al.
2013; Nishino et al. 2013; Degrauwe et al. 2016). Let-7
and its oncofetal targets have been studied intensely in
cancer, and several mechanisms for neutralizing let-7 ac-
tivity have emerged. Besides genetic deletion (Calin 2004),
biogenesis of let-7 is suppressed by Lin-28, another devel-
opmentally regulated RBP family (Viswanathan et al.
2008; Molenaar et al. 2012; Madison et al. 2013). Further-
more, alternative 3′ untranslated region (UTR) usage by
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Imp1 and Hmga2 promotes transformation (Mayr et al.
2007; Mayr and Bartel 2009). A more recent study de-
scribed a novel mechanism in neuroblastoma, where ex-
cessive amplification of Myc mRNA might sponge let-7
activity away from other targets (Powers et al. 2016).
Additionally, Imp1–3 may sequester Hmga2, Lin-28, and
other mRNA targets by directly binding let-7 target sites
to impede miRNA activity or modulate the association
of transcripts with RISC (Jonson et al. 2014; Busch et al.
2016; Degrauwe et al. 2016; Ennajdaoui et al. 2016).
Thus, in cancer, inhibition of let-7 activity and extensive
coregulation among its oncofetal targets are thought to
synergize to promote oncogenesis.
Beyond perturbation of individual miRNAs in cancer,
global miRNA deregulation through impairment of the
miRNA processing machinery drives tumor development
(Melo et al. 2009, 2010; Walz et al. 2015; Wegert et al.
2015). Mouse models have demonstrated that global
miRNA loss through reduced Dicer expression promotes
tumorigenesis (Kumar et al. 2007, 2009). In humans, germ-
line or somatic Dicer mutations predispose patients to
cancer and are collectively defined as Dicer1 syndrome
(Foulkes et al. 2014). Germline loss-of-functionmutations
in Dicer have been identified in pediatric pleuropulmo-
nary and pituitary blastomas, familial cystic nephroma,
and Wilms’ tumor (Hill et al. 2009; Bahubeshi et al. 2010;
Foulkes et al. 2011; de Kock et al. 2014). Hypomorphic
somaticmutations inDicer, primarily altering its catalytic
residues, areassociatedwithmultiple cancer types (Heravi-
Moussavi et al. 2012; Rakheja et al. 2014;Chen et al. 2015).
It is unclear why a global reduction in miRNAs pro-
motes cancer (Heravi-Moussavi et al. 2012; Chen et al.
2015). Here, we used a cell-based model of miRNA loss
and subsequent reconstitution to identify miRNA-regu-
lated gene networks and characterize their effects on tu-
morigenesis. In immortalized Dicer-null (knockout)
mesenchymal stem cells (MSCs), a fibroblast cell type,
we restored global miRNA expression and subsequent
post-transcriptional activity by stably re-expressingDicer.
Although post-transcriptional repression by let-7 and oth-
er miRNAs is restored, there persists a gene signature of
transcriptionally up-regulated oncogenes, including the
let-7-regulated Imp1–3 family,whose derepression is large-
ly resistant to Dicer and let-7 restoration. These Dicer-
rescued cells are highly tumorigenic, consistent with
expression of this oncogenic signature. Expression of this
oncogenic network is reinforced in a feedback loop by
three of its members; namely, Imp1–3. Demonstrating
clinical relevance, this set of irreversibly activatedmiRNA
targets is associated with poor survival in cancer patients.
Results
Human Dicer (hsDicer) restores global miRNA
expression in murine Dicer knockout fibroblasts
Previously, we reported the generation of SV40-large
T immortalized Dicer wild-type and knockout MSCs as
a model system for delineating gene networks regulated
by miRNAs (Ravi et al. 2012). miRNA loss throughDicer
deletion results in dramatic up-regulation of known onco-
fetal let-7 targets, such as Hmga2 and Imp1–3, that are
highly expressed in both embryos and tumors. Beyond
loss of miRNA-mediated post-transcriptional repression,
these genes exhibit evidence of transcriptional up-regula-
tion (Gurtan et al. 2013; Gosline et al. 2016).
To investigate the reversibility of previously observed
post-transcriptional and transcriptional changes resulting
from global miRNA loss, we expressed hsDicer in mono-
clonal knockout MSCs in which the endogenous murine
Dicer had been ablated previously (Dicer−/− in Fig. 1A).
Specifically, we HA-Flag-epitope-tagged and cloned wild-
typehsDicer into a retroviral construct, infectedknockout
MSCs, and selected with puromycin for a heterogeneous
population of cells. Introduction of Dicer was well tolerat-
ed with no evidence of cell death due to re-expression of
miRNAs. Protein analysis on these stable lines indicated
robust expression of both the tag and hsDicer (Fig. 1B).
Northern blots on two monoclonal cell lines
Figure 1. hsDicer rescues murine miRNA expression. (A) Sche-
matized experimental design. Wild-type hsDicer was HA-Flag-
epitope-tagged at the N terminus and cloned into pMMP-Puro,
a puromycin-resistant vector. SV40-large T immortalized
Dicerf/f or Dicer−/− cells were infected with virus encoding the
Vec or HA-Flag-hsDicer (hsDicer), drug-selected, and passaged
prior to experiments. (B, top panel) Western blot analysis across
the heterogeneous population of resistant cells. p107 is shown
as a loading control. (Bottom panel) Representative Northern
blot analysis across a set of monoclonal lines isolated by low-den-
sity seeding from the heterogeneous population of resistant cells.
U6 is shown as a loading control. (C ) Global miRNA profile com-
parison between wild-type Vec and hsDicer. miRNAs collapsed
by TargetScan family. The indicated values are normalized aver-
age expression counts across both replicates within each condi-
tion (two wild-type clones and two hsDicer clones). (Black line)
y = x; (red line) line of best fit. (D) Normalized expression counts
for the 12 TargetScan miRNA families that show significant
Ago2 cross-linking at their target sites over background (Bosson
et al. 2014). Adjusted P-value = 1 for all comparisons.
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(independently isolated from the stable heterogeneous
populations) revealed abundant expression of highly ex-
pressed miRNAs, including let-7c and miR-22, in the pa-
rental wild-type MSCs expressing an empty vector (wild-
type Vec). These miRNAs are undetectable in the corre-
sponding knockout MSCs (knockout Vec in Fig. 1B), but
stable expression of wild-type hsDicer resulted in levels
of mature miRNAs similar to the parental wild-type (Fig.
1B). Thus, hsDicer was stably expressed and functional
in processing murine pre-miRNAs to mature miRNAs.
To globally profile the miRNAs expressed across these
cell lines, we performed sequencing of the small RNA
population (small RNA-seq) on each independent clone.
We observed strong reproducibility between the clones
(Supplemental Fig. 1A,B). On average, mature miRNAs
comprised ∼21% of all reads in wild-type cells but only
1% in the Dicer nulls, demonstrating depletion of mature
miRNAs globally (Supplemental Fig. 1C). Consistentwith
the Northern blot results, expression of wild-type hsDicer
restored mature miRNAs to levels comparable with wild-
type cells (18%of all reads) (Supplemental Fig. 1C; Supple-
mental Table S1A). More than 250 miRNAs were detect-
able in both wild-type clones at a threshold of at least five
reads per million. The 10most abundant miRNAs includ-
ed miR-143, miR-100, miR-22, and multiple members of
the let-7 family (Supplemental Table S1B). Upon collaps-
ing by seeds, the let-7 family was most abundant, consti-
tuting, on average, 37% of reads mapping to miRNAs
(Supplemental Table S1C).
We then directly compared the wild-type and hsDicer
reconstituted miRNA libraries using DE-Seq (Anders
and Huber 2010). The expression of miRNA families
was largely restored to wild-type levels (Fig. 1C). The var-
iation between wild type and hsDicer observed at lowly
expressed/nonexpressed miRNAs was not statistically
significant, and, globally, only three small RNAs could
be assessed as significantly different. These three are all
low abundance and together constitute <0.5% of the
miRNA population (Supplemental Fig. 1D; Supplemental
Table S1D). Notably, let-7, the most abundant seed fam-
ily, was almost identically expressed between wild type
and hsDicer (Fig. 1B,D). To consider other dominant
seeds, we evaluated the 12 most active miRNA seeds in
MSCs, as defined by statistically significant genome-
wide Ago2-dependent cross-linking (iCLIP [individual-
nucleotide-resolution UV cross-linking and immunopre-
cipitation]) at their target sites (Bosson et al. 2014). Im-
portantly, these 12 families were all completely
restored at the mature miRNA level with hsDicer recon-
stitution (P = n.s.) (Fig. 1D; Supplemental Table S1D). To-
gether, these results show that stable wild-type hsDicer
expression in a Dicer−/− background returns the mature
miRNA expression profile to the parental wild-type
(Dicerf/f) state.
hsDicer expression completely reconstitutes endogenous
miRNA activity
To determinewhethermiRNAs generated by hsDicerme-
diate repression ofmRNA targets, we used a previously re-
ported two-color fluorescent reporter (Mukherji et al.
2011; Wilusz et al. 2012) to compare post-transcriptional
miRNA activity between parental wild type and hsDicer.
A bidirectional promoter drives the expression of
mCherry-containing miRNA-binding sites in its 3′ UTR
and nontargeted eYFP that serves as an internal control
(Fig. 2A). We measured the repression mediated by
miRNAs representing a range of expressions. In wild-
type Vec cells, compared with a nontargeted mCherry
control (“0x”), the addition of miRNA-binding sites
resulted in an average of 1.3-fold repression for the lowly
expressed miR-24 and 5.3-fold repression for the more
abundant let-7 (Fig. 2A). Remarkably, we observed 1.2-
fold and 5.5-fold repression for these miRNAs, respective-
ly, in wild-type hsDicer-expressing cells (Fig. 2A). These
results are consistent across the second population of
clones (data not shown). Hence, the levels of repression
across all testedmiRNAs are not statistically different be-
tween wild-type Vec and hsDicer-expressing cells (P-val-
ue = 0.71) (Fig. 2A). Furthermore, there was negligible
repression of the reporters in knockout Vec cells, confirm-
ing that these cells are indeed miRNA-deficient (Fig. 2A).
We next examined whether the above results could be
extended to endogenous targets. To do so, we carried out
mRNA sequencing (mRNA-seq) on poly(A)-selected total
RNA isolated from both clones of each cell type. We de-
tected just under 13,000 genes expressed across all condi-
tions (Supplemental Table S2A). A pairwise comparison of
the transcriptomes of wild-type Vec and knockout Vec
identified a population of 1524 differentially expressed
genes that exhibited a median up-regulation of approxi-
mately threefold and down-regulation of ∼3.6-fold (Sup-
plemental Fig. 2A; Supplemental Table S2B). The degree
of change occurring with Dicer loss showed a strong and
significant correlation to previously reported expression
changes in MSCs (Supplemental Fig. 2B; Gurtan et al.
2013). Gene set enrichment analysis (GSEA) (Subrama-
nian et al. 2005) confirmed that the most up-regulated
genes were enriched for targets of “active”miRNAs (Sup-
plemental Fig. 2C).
To perform a more miRNA-focused comparison of cell-
based activity on endogenous targets, we derived empiri-
cal cumulative distributive functions for TargetScan
miRNA families expressed in wild-type Vec cells. Upon
loss of Dicer, conserved targets of most miRNAs were
up-regulated, with let-7 showing the most significant
change (Fig. 2B, miRNAs whose targets significantly
change statistically are shown in blue). The significant
up-regulation indicates strong silencing of targets in the
wild-type state. hsDicer expression in the Dicer knock-
out background resulted in significant repression of con-
served targets (Fig. 2B), indicating that the restored
miRNAs were highly active. Notably, targets of more
abundant and “active” miRNA seeds (such as let-7,
miR-17, miR-199, and miR-30) that showed significant
up-regulation upon Dicer loss exhibited median down-
regulation comparable with hsDicer. Hence, hsDicer
comprehensively restores miRNA activity on endoge-
nous targets to a degree comparable with the parental
wild-type state.
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Finally, as miRNAs are known to buffer changes due to
environmental stress (Leung and Sharp 2010), we tested
for Dicer-dependent changes in stress response by treating
the cells with the DNA-damaging agent doxorubicin.
Knockout Vec cells were highly sensitive to this drug
compared with wild-type Vec (P < 0.05) (Fig. 2C). Expres-
sion of hsDicer in knockout cells completely rescued
the doxorubicin-induced cell death at all concentrations
tested such that the responses between wild-type Vec
and hsDicer were indistinguishable (P = 0.77) (Fig. 2C). To-
gether, these results demonstrate that, on a global scale,
hsDicer expression completely restores miRNA post-
transcriptional activity, which in turn is sufficient to res-
cue miRNA loss-induced stress defects.
let-7 oncofetal targets remain activated after restoration
of Dicer
Next, we examined the expression of oncofetal targets re-
ported previously to contribute to the let-7 signature in
Dicer knockout MSCs (Gurtan et al. 2013). Since our
data indicate full reconstitution of miRNA expression
and activity, we hypothesized that the expression of these
targets would revert to levels observed in wild-type Vec.
Quantitative PCR (qPCR) analysis showed a dramatic
up-regulation of Imp family proteins upon Dicer loss,
from 45-fold for Imp2 to upward of 200-fold for Imp1
and Imp3 (Fig. 3A). Hmga2, an additional let-7 oncofetal
target that is often correlated with Imp2–3 in expression,
was up-regulated to a lesser degree (∼17-fold) (Fig. 3A).
These fold changes are consistent with the RNA-seq re-
sults (Supplemental Fig. 3A).
Surprisingly, restoration of miRNA activity with the
introduction of hsDicer only marginally down-regulated
Imp mRNA expression relative to knockout Vec levels
(Fig. 3A). Imp mRNAs that were up-regulated 45-fold
to 200-fold were suppressed only twofold to fourfold
with restoration of miRNA activity. Less dramatically,
Hmga2 mRNA, which increased 17-fold with loss of
miRNAs, was suppressed fourfold upon restoration
with hsDicer. At the protein level, Western blot analysis
mirrored the mRNA results. While Hmga2 was very low-
ly expressed and the Imp family was undetectable in
wild-type Vec, all four genes showed robust protein ex-
pression in knockout Vec cells (Fig. 3B). Subsequent to
miRNA rescue with hsDicer, Imp1–3 all showed a partial
reduction consistent with the typical post-transcription-
al repression by miRNAs. Importantly, even after resto-
ration of miRNA activity, all three genes were highly
expressed compared with original wild-type cells (Fig.
3B). In contrast, Hmga2 protein expression was more sig-
nificantly repressed than the Imp family. This is con-
sistent with the mRNA results, where, in hsDicer
cells, Hmga2 was only approximately fourfold more
highly expressed than in wild-type Vec (Fig. 3A; Supple-
mental Fig. 3A).
The inability of complete miRNA reconstitution to
revert Imp gene expression suggests that somatic Dicer
loss activates a self-sustaining “oncofetal-dependent”
state. This possibility is consistent with our previous
studies showing major transcriptional changes occurring
at these loci upon Dicer loss (Gurtan et al. 2013; Gosline
et al. 2016). Hence, we evaluated the transcriptional
state at these loci through chromatin immunopreci-
pitation (ChIP) followed by massively parallel DNA se-
quencing (ChIP-seq) on H3K4me3 and H3K36me3
modifications. Upon inspection of the Imp2 locus, we ob-
served increased H3K4me3 near the transcription start
Figure 2. hsDicer expression recovers miRNA activi-
ty. (A, top panel) Schematic of the dual-color reporter
used to assay miRNA repression. The 3′ UTR of
mCherry contains sites imperfectly complementary
to the miRNA of interest. The let-7c sequence is
shown in purple. (Bottom panel) After transfecting
with the reporter, flow cytometry was used to measure
mCherry and eYFP levels. For each cell type, fold re-
pression is relative to the nontargeted 0x reporter.
Data shown are the mean and standard deviation of
three independent experiments. P-values were calcu-
lated by paired Student’s t-test. (B) Scatter plot of the
median change in expression ofmiRNA targets relative
to control genes matched for 3′ UTR length, GC con-
tent, and expression. Each point represents conserved
targets of a single TargetScan miRNA family. miRNA
expression is based on the average wild-type Vec ex-
pression reported in this study. Only expressed miR-
NAs are shown. (Blue) Significant change (Wilcoxon
rank sum P≤ 0.05); (red) not significant. (C ) Doxorubi-
cin-induced apoptosis measured by caspase-3 cleavage.
The mean ± SEM of three independent experiments is
indicated. P-values were calculated by unpaired Stu-
dents t-test. (∗) P < 0.05; (n.s) not significant.
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site (TSS) and H3K36me3 toward the 3′ end of the gene
body in knockout Vec compared with wild-type Vec cells
(Fig. 3C). Intriguingly, add-back of hsDicer effected negli-
gible change from the knockout condition, indicating that
there was “miRNA-resistant” transcriptional activity
across this locus in hsDicer cells compared with the
wild-type Vec. As a control comparison, the flanking
gene Senp2 was indistinguishable across all three condi-
tions for both modifications (Fig. 3C). These results
indicate a targeted miRNA-resistant transcriptional acti-
vation of Imp2 upon Dicer loss.
This trend was observed for the other Imp family mem-
bers but not forHmga2, which showedno evidence ofDic-
er-dependent transcriptional changes (Supplemental Fig.
3B–D). As mentioned above, the degree of up-regulation
for Hmga2 at the mRNA level was substantially less
than that of the other oncofetal targets. Given that the
Hmga2 3′ UTR has seven let-7 seed matches (of which
six are conserved), we speculate that the 17-fold up-regu-
lation is due primarily to multiplicative or cooperative
post-transcriptional miRNA effects (Doench et al. 2003;
Grimson et al. 2007; Saetrom et al. 2007). For the other
oncofetal targets, however, we propose that transcription-
al changes upon Dicer loss account for most of their up-
regulation (beyond directmiRNAeffects onmRNAstabil-
ity), and this change is not reversed upon restoration of
miRNA activity.
Transcriptomic profiling reveals a larger, miRNA-
resistant gene expression signature
We tested whether the irreversible behavior of the oncofe-
tal let-7 targets Imp1–3was part of amore global phenom-
enon. To do this, we used an unsupervised blind source
separation approach using independent component analy-
sis (ICA) (Hyvarinen and Oja 2000) to identify distinct
gene expression signatures. We used this approach previ-
ously to elucidate cancer-associated gene signatures in
lung adenocarcinoma (Li et al. 2015; Dimitrova et al.
2016; Papagiannakopoulos et al. 2016). ICA provides the
ability to detect statistically independent gene expression
signatures within the context of the entire data set (i.e.,
across all samples), as opposed to performing multiple
pair-wise differential expression analyses. When applied
to the mRNA-seq data across all cell lines, ICA identified
two significant and biologically relevant signatures (P =
0.01) (Fig. 4A): Signature 1 reflects a pattern of gene up-reg-
ulation in both knockout Vec and hsDicer conditions rel-
ative to parental wild-type, while signature 2 indicates a
pattern of higher gene expression in miRNA-deficient
conditions relative to miRNA-competent ones (Fig. 4A).
qPCR analysis of a sampling of signature 1-correlated
genes (z-score >3) (Supplemental Table S3) confirmed
that hsDicer reconstitution did not revert their expression
to wild-type levels (Fig. 4B). In contrast, signature 2-relat-
ed genes showed near complete rescue to wild-type ex-
pression levels (Fig. 4C). As such, hereafter, signature 1
and signature 2 are referred to as miRNA-resistant and
miRNA-sensitive, respectively. Consistent with the
observations for the Imp1–3 family, as a group, the
miRNA-resistant genes were dramatically up-regulated
uponDicer loss, significantlymore so thanmiRNA-sensi-
tive genes (Fig. 4D). Upon quantification of the ChIP-seq
signal at promoters, we observed that the miRNA-re-
sistant genes exhibited significantly higher gains in
H3K4me3 than reversible genes (Fig. 4E, cf. second and
third box plots) when Dicer was originally lost in these
cells. With hsDicer add-back, there was no significant re-
duction in H3K4me3 at the miRNA-resistant genes (Fig.
4E, cf. second and fifth box plots), while H3K4me3 at
the miRNA-sensitive genes was significantly reduced
(Fig. 4E, cf. third and sixth box plots). A similar trend
was observed for H3K36me3 in the body of genes (Fig. 4F).
Thus, ICA uncovered a broader miRNA-resistant gene
set beyond Imp1–3 that exhibits dramatic up-regulation
upon Dicer loss followed by incomplete repression to
wild-type expression. Our results indicate that increased
transcription (measured through ChIP-seq) strongly corre-
lates with this resistance (Fig. 4D–F). Therefore, we de-
fined a “high-confidence” set of miRNA-resistant genes
due to changes in transcription using our combined data
sets. We overlapped the set of genes defined by ICA (signa-
ture 1: z-score >3; n = 87) with genes that show a log2 chan-
ge of at least 1.4-fold in their associated H3K4me3 peaks
in both knockout Vec and hsDicer compared with wild-
type Vec (knockout Vec/wild-type Vec≥ 1.4; hsDicer/
wild-type Vec≥ 1.4; n = 139) (Supplemental Tables S3,
S4). This analysis identified a set of 28 genes that we
Figure 3. Despite miRNA rescue, let-7 oncofetal targets re-
main activated. (A) qPCR analysis of four let-7-regulated oncofe-
tal genes. Note the logarithmic scale. For each gene, expression
is relative to wild-type Vec levels. Data are plotted as the mean
± SEM of four or more independent experiments. (B) Western
blot analysis of the oncofetal gene set. HA tag was used to indi-
cate hsDicer expression. Actin was used as a loading control. (C )
Normalized read counts for H3K4me3 and H3K36me3 marks at
the Imp2 locus across the three cell lines. Within each chroma-
tin mark, all conditions are set to the same scale. Flanking genes
are shown as controls. Arrows indicate transcription start sites
(TSSs).
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designate as “high-confidence miRNA-resistant” genes
(Fig. 4G; Supplemental Table S3). In contrast, an overlap
using miRNA-sensitive genes (signature 2: z-score >3; n
= 112) with the same H3K4me3 gene set was insignificant
and contained only three genes (P = 0.12) (data not shown).
These results indicate that transcriptional activation is a
feature of miRNA-resistant genes.
miRNA restoration confers a stably inherited
transformed phenotype
The high-confidence miRNA-resistant signature includes
let-7-regulated oncogenes that are elevated dramatically
in various cancers and function to promote tumor growth,
drug resistance, andmetastasis (Tessier et al. 2004; Boyer-
inas et al. 2008; Samanta et al. 2013). Thus, we examined
whether re-expression of hsDicer and hence miRNAs in
Dicer knockout cells resulted in a tumorigenic pheno-
type. In a soft agar assay, hsDicer cells exhibited signifi-
cant growth potential not observed for wild-type Vec
and knockout Vec cells (Fig. 5A). These results suggest
that hsDicer cells acquired properties of anchorage-inde-
pendent growth and anoikis resistance, which could pos-
sibly contribute to tumorigenicity in vivo. To directly
test this possibility, we performed subcutaneous injec-
tions of wild-type Vec, knockout Vec, and hsDicer cells
into the flanks of immune-compromisedmice. Strikingly,
we observed 100% incidence of tumor formation with
hsDicer cells but none for wild-type Vec or knockout
Vec (P = 3 × 10−07) (Fig. 5B). Histopathological analysis of
the tumors indicated undifferentiated sarcomas, which
is consistent with the mesenchymal origin of these cells
(Fig. 5C).
To confirm that the tumors were of hsDicer cell origin,
we generated cell lines from five tumors and confirmed
the absence of endogenous murine Dicer via PCR geno-
typing (Supplemental Fig. 4A). Furthermore, the tumor
cells were all puromycin-resistant due to the vector con-
taining hsDicer (data not shown) and strongly expressed
let-7 and other mature miRNAs, thereby confirming the
retention of hsDicer in vivo (Supplemental Fig. 4B). Im-
portantly, a sampling of a subset of miRNA-resistant
genes indicates that they were highly expressed in all of
the tumor cell lines (Supplemental Fig. 4C,D). Thus, we
conclude that the observed tumors developed from
hsDicer cells.
Our results indicate that only hsDicer cells are tumori-
genic despite the fact that knockout Vec cells also have
high expression of Imp1–3 and other high-confidence
miRNA-resistant genes. To evaluate whether miRNA
deficiency adversely impacted growth of knockout Vec
cells, we measured doubling times and apoptosis for
each genotype. Knockout Vec cells exhibited a signifi-
cantly slower doubling, while hsDicer completely rescued
Figure 4. Identification of a high-confidence miRNA-
resistant gene signature. (A) Heat map depicting two in-
dependent, statistically significant gene signatures de-
tected in the RNA-seq expression data set using ICA.
Signature 1 (Sig1) represents an expression pattern of
genes up-regulated in knockout Vec and hsDicer condi-
tions relative to wild-type Vec. Signature 2 (Sig2) repre-
sents genes that are down-regulated to wild-type Vec
levels upon introduction of hsDicer. (B,C ) qPCR valida-
tion of “irreversible” or “miRNA-resistant” genes identi-
fied from signature 1 (B) and “reversible” or “miRNA-
sensitive” genes identified from signature 2 (C ). Results
are plotted relative towild-typeVec levels. Bars represent
mean ± SEM of at least three independent experiments.
(D) Box andwhisker plots of normalizedRNA-seq expres-
sion fold changes for all expressed genes (n = 12834),
signature 1-correlated genes (n = 87), and signature 2-cor-
related genes (n = 112). (E,F ) Same as in D but for fold
changes in normalized counts for gene-associated
H3K4me3 peaks (E) and H3K36me3 peaks (F ). Whiskers
represent the 10th–90th percentile, and all other points
are shown as individual dots. The P-valueswere calculat-
ed byMann-WhitneyU-test. (∗∗) P < 0.01; (∗∗∗) P < 0.0001;
(n.s) not significant. (G) Overlap of signature 1-correlated
genes and genes with a log2 fold change of at least 1.4 in
H3K4me3 peak counts near their TSSs. The H3K4me3
criteria is satisfied by both knockout Vec/wild-type Vec
and hsDicer/wild-type Vec comparisons.High-confidence
miRNA-resistant genes are listed. The hypergeometric
test’s P-value is indicated.
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this phenotype (Fig. 5D). In addition, knockout Vec cells
exhibited an elevated basal apoptosis at high culture den-
sity compared with wild-type Vec and hsDicer (Fig. 5E). In
vivo, these combined defects are probably deleterious to
knockout Vec cells and dominate over any oncogenic
potential.
The high-confidence miRNA-resistant gene set
is a pan-cancer signature
To assess the relevance of the high expression levels of
this high-confidencemiRNA-resistant network that is en-
riched in oncofetal genes, we first queried the cBioPortal
database (Cerami et al. 2012). A cross-cancer analysis re-
vealed a high degree of alterations in this gene set in
breast, lung, bladder, and pancreatic cancers (Supplemen-
tal Fig. 4E). Notably, these alterations were predominant-
ly amplifications, suggesting oncogenic activity that is
important for human malignancy. To address this more
directly, we examined whether the high-confidence
miRNA-resistant gene signature could provide prognostic
information relevant to human cancer. Using gene expres-
sion profiles and clinical information from The Cancer
Genome Atlas’s (TCGA; http://cancergenome.nih.gov)
pancreatic adenocarcinoma (PAAD) cohort, we found
the signature to be strongly correlated with clinical out-
come: High expression was significantly associated with
worse survival in Kaplan-Meier analysis comparing pa-
tients at the extremes of the signature correlation score
distribution (|z| > 0.5; log-rank P < 0.0005) (Fig. 5F). Fur-
thermore, increasing signature correlation score was also
associated with poor prognosis across all patients in the
cohort (Hazard ratio = 1.51) in a Cox proportional hazard
model while controlling for various other clinical covari-
ates (Fig. 5G), suggesting that this signature is indepen-
dently prognostic in PAAD. To assess the pan-cancer
relevance of this signature, we investigated additional
cancer types within the TCGA data set. Strikingly, this
signature is also significantly correlated with reduced sur-
vival across other solid cancers (lung, kidney, and glioblas-
toma/low-grade glioma) (Supplemental Fig. 4F), indicating
that up-regulation of this high-confidence miRNA-resis-
tant gene set is a more general feature of human cancers.
Cotargeted disruption of Imp1–3 adversely impacts
hsDicer tumorigenicity
The miRNA-resistant signature identified in this study is
almost certainly oncogenic in human cancer. However, it
is unclearwhether a core subset of these genes is primarily
responsible for the tumorigenicity of the hsDicer cells. To
investigate this, we focused on the Imp family because
Imp1–3 are not expressed in most adult tissues and are of-
ten de novo activated in cancers. To test whether loss of
any Imp member would negatively affect tumorigenesis,
we used the CRISPR–Cas9 system to generate individual
knockouts of Imp1–3 in hsDicer cells and propagated
two independent clones of each knockout cell line.
Figure 5. miRNA restoration through hsDicer expres-
sion transformsMSCs. (A) Colony formation ofMSCs af-
ter ∼15 d of growth in agarose-containing medium.
Representative 4× bright-field images for each genotype
are shown. Colonies were counted by eye in five random
fields for three independent experiments. Data are plot-
ted as themean ± SEM. The Student’s t-test P-value is in-
dicated. (B) Frequency of tumor formation by the three
parental MSC lines 8 wk after injection of 105 cells into
the flanks of immune-compromised mice. (C ) Represen-
tative hematoxylin and eosin staining of an hsDicer tu-
mor section at 20× magnification. Bar, 200 µm. (D)
Proliferation assay indicating the mean ± SEM of two ex-
periments with two replicates each. (E) Apoptosis as-
sayed by capase-3 cleavage. Mean and standard
deviation are plotted. P-values were calculated by Stu-
dent’s t-test. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.0001; (n.
s) not significant. (F ) Kaplan-Meier survival analysis of
The Cancer Genome Atlas’s (TCGA) pancreatic adeno-
carcinoma (PAAD) patients stratified by their correlation
score with the high-confidence miRNA-resistant signa-
ture. |z| > 0.5 extremes of score distribution; n = 46 most
correlated; n = 28 least correlated. Patients with most
correlated gene expression scores (red) exhibit signifi-
cantly reduced survival times compared with least corre-
lated patients (blue). See the Supplemental Material for
details. (G) Results of univariate and multivariable Cox
proportional hazard model on overall survival in the
TCGA PAAD cohort (all patients). The high-confidence
miRNA-resistant signature is found to be independently
prognostic within the cohort of TCGA PAAD patients.
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Western blot analysis indicated complete loss of the indi-
vidual Imp proteins in the targeted clones, and the results
of genomic DNA sequencing were consistent with a loss
of the reading frame (Fig. 6A; data not shown). However,
each Imp knockout retained robust expression of the re-
maining two familymembers, suggesting a lack of coregu-
lation. We then evaluated the potential of the Imp
knockouts to grow in vitro via the soft agar assay. Individ-
ual loss of Imp1–3 in hsDicer cells did not confer any
meaningful reduction in colony formation (Fig. 6B; Sup-
plemental Fig. 5A). As an alternative measure of tumori-
genic potential, we used the growth in low attachment
(GILA) assay, which has been shown to capture aspects
of transformation that could bemissed by soft agar growth
(Rotem et al. 2015). We validated that GILA recapitulated
the soft agar results; only hsDicer cells were able to grow
over a 7-d time course in GILA (Supplemental Fig. 5B). In
contrast, wild-type Vec and knockout Vec cells under-
went anoikis despite exhibiting strong growth under nor-
mal adherent conditions (Supplemental Fig. 5B; data not
shown). Consistent with the soft agar results, individual
knockouts of Imp1–3 did not dramatically reduce cellular
growth via GILA (Fig. 6C). Hence, our data indicate that
loss of any one Imp family member on the background
of the endogenous expression of the other two Imp pro-
teins is not sufficient to abrogate the tumorigenic proper-
ties of hsDicer cells.
Given this result, we next explored the effects of simul-
taneous loss of all three Imp proteins in the hsDicer con-
dition. We isolated two independent clones of these
triple-knockout cells, designated ImpΔ3, and confirmed
loss of function by Western blot and genomic DNA
sequencing (Fig. 6D; Supplemental Fig. 5C). These clones
exhibited a significant reduction in the number of
colonies formed in soft agar as compared with the
hsDicer cells from which they were derived (Fig. 6E).
Similarly, the growth of both ImpΔ3 clones was severely
compromised in the low adherent conditions of the
GILA assay (Fig. 6F). To extend these results in vivo,
we performed subcutaneous tumor formation assays in
immune-compromised mice, injecting the parental
hsDicer cells and ImpΔ3 cells in the left and right flanks,
respectively, of each mouse. hsDicer-derived tumors
first appeared after 28 d compared with 35 d for ImpΔ3
(Fig. 6G). ImpΔ3 cells required ∼42 d to form tumors at
50% of the sites of injection, while 90% of sites injected
with hsDicer cells had formed tumors at that time point
(Fig. 6G). To better assess this difference in tumorigenic-
ity, we measured the growth of tumors with time.
The ImpΔ3 tumors that formed grew at a significantly
reduced rate, ultimately resulting in dramatically stunt-
ed tumors when compared with the parental hsDicer
tumors (P < 0.05) (Fig. 6H,I). Histologically, the ImpΔ3
tumors were undifferentiated sarcomas with pleomor-
phic nuclei, similar to hsDicer-derived tumors (data not
shown). Altogether, these data demonstrate that the
combined activation of the Imp family is important for
the oncogenic switch acquired by Dicer-rescued cells
and that additional miRNA-resistant genes may contrib-
ute to tumorigenesis.
Imp1–3 reinforce expression of miRNA-resistant genes
To understand themechanism by which combined loss of
Imp1–3 effects this reduced tumorigenicity, we used poly
(A)-selected RNA-seq to analyze the steady-state mRNA
levels in ImpΔ3 and the parental hsDicer cells. Upon loss
of Imp1–3 proteins, 302 genes were significantly differen-
tially expressed (fold change≥2; false discovery rate [FDR]
≤0.05) (Supplemental Table S5). Two-hundred-seven
genes were up-regulated compared with hsDicer with a
median fold change of 2.9, while 95 genes were down-reg-
ulated approximately sixfold on average (Fig. 6J; Supple-
mental Fig. 5D). First, we queried whether loss of Imp1–
3 predominantly affected other members of the high-con-
fidence miRNA-resistant signature. Only five genes from
this signature were significantly differentially expressed
(Supplemental Fig. 5E), and, globally, these were not bi-
ased to either the highly up-regulated or down-regulated
genes (Fig. 6K). Given this result, we extended the analysis
to include the larger set of miRNA-resistant genes from
which the high-confidence set had been derived (ICA sig-
nature 1, z > 3; n = 87) (Fig. 4G). GSEA revealed that ICA
signature 1-associated genes were significantly enriched
among genes down-regulated by Imp1–3 loss, 12 of which
met the significance threshold for differential expression,
and, of these, 11 decreased in expression (the exception be-
ing Msln) (Fig. 6K; Supplemental Fig. 5F). This indicates
that the majority of the genes that were strongly up-regu-
lated in knockout Vec and hsDicer cells, but lacked tran-
scriptional activation, was stabilized by expression of
Imp1–3.
We then examined the GSEA leading edge subset,
which constitutes the core group of genes accounting for
this enrichment and reflects the genes most biologically
important for the phenotype of interest (in this case,
Imp1–3 loss), and noticed a strong contribution from
high-confidence miRNA-resistant genes (Supplemental
Table S6). Consistent with expression changes being spe-
cific to Imp1–3 activity, in all, 10 of the 44 genes compris-
ing the leading edge have been implicated as direct Imp1–
3 targets (statistically significant signal in either CLIP or
RNA immunoprecipitation data sets) across studies in
pluripotent stem and pancreatic cancer cells (Supplemen-
tal Table S6; Taniuchi et al. 2014; Conway et al. 2016;
Ennajdaoui et al. 2016). This included, butwas not limited
to, components of the high-confidence miRNA-resistant
signature that we found to be prognostic in human can-
cers: Sox11, Traf1, and Flrt2. However, the leading edge
gene set was also populated by oncogenes that have not
been formally linked with Imp1–3, such as Plag1 and
Fzd6. To explore potentially novel relationships, we as-
sessed expression patterns of leading edge genes in cancer.
Slpi, Plag1, and Fzd6 showed strong correlation with
Imp1–3 family members in pancreatic tumors (Fig. 6L),
and this trend was consistent in kidney and lung tumors
as well (Supplemental Fig. 5G,H). This observation impli-
cates Slpi, Plag1, and Fzd6 as genuine downstream effec-
tors of Imp1–3 oncogenic activity in our cell system and
human cancers. In summary, in hsDicer cells, Imp1–3 pri-
marily sustain a post-transcriptional up-regulation of
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Figure 6. Combined loss of Imp1–3 greatly impairs tumorigenicity in vivo. (A) Western blot of lysates derived from CRISPR–Cas9-gen-
erated Imp knockout cells. Two independent clones of each knockout cell type are indicated. (Left panel) Imp1 knockouts (the upper band
is the specific band). (Middle panel) Imp2 knockouts. (Right panel) Imp3 knockouts. Vinculin was used as a loading control. (B) Quanti-
fication of soft agar colony counts from the cell lines depicted inA. Data are plotted as themean ± SEM. (C ) Growth time course of cells in
GILA assay. The ATP yield at each time point is a measure of cell viability. Data are plotted as the mean ± standard deviation. n = 3. (D)
Western blot of whole-cell lysates from two independent clones of CRISPR–Cas9-generated Imp1–3 triple-knockout (ImpΔ3) cells. Actin
was used as a loading control. (E) Quantification of soft agar colony counts from the cell lines depicted in D. Representative bright-field
soft agar images for each genotype are shown at 4× magnification. (F ) Same as inC but for ImpΔ3 cells. (G) Cumulative fraction of injected
sites where tumors formed as a function of time. Each mouse from this cohort was subcutaneously injected with two cell types: hsDicer
cells on the left flank and ImpΔ3 cells on the right flank. n = 10. (H) Kinetics of subcutaneous tumor growth for hsDicer- and ImpΔ3-derived
tumors. (∗) P < 0.05 from paired Wilcoxon signed rank test. (I ) Representative image depicting gross subcutaneous tumor sizes at the ex-
perimental end point (64 d after injection). Black and yellow arrows indicate sites of hsDicer or ImpΔ3 cell injection, respectively. (J) Heat
map of the 302 genes differentially expressed between hsDicer and ImpΔ3 cells. For each gene (each row), normalized gene expression is z-
score standardized. (K ) GSEA plots for the high-confidence miRNA-resistant (left panel) and ICA-derived (right panel) signature 1 signa-
tures. Genes are ranked according to descending (ImpΔ3/hsDicer) log2 fold change such that most down-regulated genes are skewed to the
right of the plot. Nominal P-values and false discovery rate (FDR) q-values are indicated. (L) Heat map depicting gene-by-gene Spearman
correlation coefficients in tumor samples of PAAD patients from TCGA. Depicted genes are the leading edge core genes driving the en-
richment of ICA signature 1 in K above. (M ) Summary table for GSEA results showing enriched gene sets from the Molecular Signatures
Database (MSigDB) curated or hallmark gene set collections. Genes down-regulated with Imp1–3 loss are significantly enriched for gene
sets associated with pseudopodia-, cancer-, anoikis-, and inflammation-associated signaling.
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miRNA-resistant genes populated by likely direct Imp tar-
gets and other oncogenes.
Finally, we broadened our analysis to investigate exter-
nally annotated gene sets from the Molecular Signatures
Database (MSigDB) (Liberzon et al. 2011). This unbiased
approach implicatedmultiplebiological pathwaysasbeing
perturbed upon Imp1–3 loss. For genes up-regulated in
ImpΔ3, few gene sets were enriched, amongwhich a coher-
ent biological theme was not apparent. However, among
down-regulated genes, there was significant enrichment
for transcripts localized to pseudopodia, consistent with
previously described roles for Imp1 and Imp3 (Stohr et al.
2012; Taniuchi et al. 2014; Ennajdaoui et al. 2016) as well
as genes important for avoiding anoikis and for various sig-
naling and cancer pathways (Fig. 6M). In all, this analysis
confirmed that the expression changes downstream from
Imp1–3 loss are concordant with genes and biological pro-
cesses with established importance in cancer.
Discussion
We demonstrated that loss of Dicer results in up-regula-
tion of a subset of miRNA targets that are transcriptional-
ly activated and not resilenced upon reconstitution of
miRNA expression. The expression of this miRNA-resis-
tant gene set is reinforced by at least three of its members,
Imp1–3, and is self-sustaining. The miRNA-resistant sig-
nature was observed in independently derived clones of
Dicer-restored cells.More important and surprising, these
clones were tumorigenic in contrast to their progenitors.
Finally, the miRNA-resistant gene set is associated with
poor patient prognosis across multiple cancers.
Irreversible up-regulation of oncofetal targets of let-7
Previous work has demonstrated that the most dramatic
changes in gene expression upon loss of the post-transcrip-
tional activity of miRNAs in MSCs surprisingly occur at
the transcriptional level (Gosline et al. 2016). This dra-
matic transcription activation was documented as an in-
crease in nascent RNAs, as assessed through intronic
reads, and a corresponding increase in H3K4me3 and
H3K36me3 chromatin modifications (Gosline et al.
2016). We now extend these findings by showing that res-
cue of miRNA expression and activity restored the vast
majority of changes that occurred with Dicer loss but
failed to suppress the transcriptional activation of a core
oncogenic gene set, including Imp1–3. The inability of re-
storedmiRNAs to completely suppress this oncogenic sig-
nature is surprising and reveals important principles
regarding the functional organization of miRNAs in
gene expression networks. For example, the let-7 targeted
genes Imp1–3 are highly expressed during early embryon-
ic development, but their expression dramatically de-
clines in a window that coincides with induction of
mature let-7. It is unknown whether their repression is
driven solely by let-7-mediated post-transcriptional activ-
ity or whether loss/gain of transcriptional regulators acts
on them redundantly to facilitate complete silencing in
differentiated tissues (Zhu et al. 2011; Nguyen et al.
2014). Our study demonstrates that despite the fact that
the sole loss of miRNA activity is sufficient for Imp1–3
transcriptional activation, rescue of this post-transcrip-
tional layer of regulation cannot significantly resilence
these genes. This state is distinct from induction of a plu-
ripotent state characterized by expression of Oct4, Sox2,
and Lin-28, which are not expressed in any of these
MSC-related cells. Thus, loss of miRNA activity in
MSCs activates components that are epigenetically resis-
tant to complete restoration of miRNA expression.
Transcriptional and post-transcriptional regulation in an
epigenetic switch
The observation that the cells expressing the miRNA-re-
sistant set of genes are highly malignant, whereas their
progenitor wild-type cells before loss and restoration of
Dicer are not, suggests epigenetic activation of an onco-
genic program. A stable inheritance of an acquired trans-
formed phenotype has been described elsewhere
(Iliopoulos et al. 2009). That study elucidated a positive
feedback loop between transcriptional (NF-κB regulation
of IL-6) and post-transcriptional (Lin-28b and let-7) regula-
tors as key components underlying maintenance of trans-
formation. However, neither Lin-28 paralog is expressed
in the MSCs. Furthermore, extensive perturbation of can-
didate transcriptional factors identified by computational
approaches did not identify the key mediators of the
miRNA-resistant signature’s induction (Gosline et al.
2016). While the complete mechanism underlying the
switch described in this system is unknown, the positive
feedback loop involving Imp1–3 that is activated by tem-
porary loss of Dicer partially underlies this phenomenon.
Reinforcement of sustained oncogene expression
by Imp1–3 RBPs
Disruption of let-7 regulation of oncofetal targets (Imp1–
3, Hmga2, and Lin-28) is an important aspect of oncogen-
esis and is achieved through a variety of mechanisms. Let-
7 may be genetically deleted or suppressed by Lin-28
(Calin 2004; Viswanathan et al. 2008, 2009), let-7 activity
may be sponged (Powers et al. 2016), and alternative 3′
UTR usage may mediate escape of let-7-mediated repres-
sion (Mayr et al. 2007; Mayr and Bartel 2009). Based on
the above observations on the activation of Imp1–3 in
our model system, simultaneous elevated expression of
multiple Imp proteins through transcriptional activation
may be an additionalmechanism overriding let-7 activity.
This mechanism is probably independent of observations
that Imp1–3 activity converges on post-transcriptionally
opposing let-7 and other miRNAs (Jonson et al. 2014;
Sheen et al. 2015; Busch et al. 2016). Post-transcriptional
silencing by let-7 is fully active in these tumorigenic cells.
There has been a concerted effort toward understanding
the mechanisms through which Imp1–3 exert oncogenic
effects by use of pull-down experiments to characterize
their “RNA interactomes” (Hafner et al. 2013; Taniuchi
et al. 2014; Conway et al. 2016; Ennajdaoui et al. 2016).
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Our work complements such studies by investigating the
gene expression changes and functional outcomes down-
stream from simultaneous inactivation of all Imp paralogs
and places Imp1–3 at the core of an oncogenic switch. The
protumorigenic phenotype of hsDicer cells was impaired
only with combined Imp1–3 loss and not by loss of the in-
dividual members, suggesting strong functional redun-
dancy among this family. This observation is consistent
with reports of overlapping mRNA binding as well as
autoregulation by Imp1–3 (Conway et al. 2016; Ennaj-
daoui et al. 2016). Additionally, we identified Plag1,
Fzd6, and Slpi as novel possible downstream effectors of
Imp1–3. These oncogenes belonged to the miRNA-resis-
tant signature, were strongly down-regulated by Imp1–3
loss, and exhibited correlated expression among them-
selves as well as with Imp1–3 in various human cancers.
In summary, we described an oncogenic switch involv-
ing the conversion of nontransformed fibroblasts to stable
transformed cells by toggling the activity of miRNAs off
and on. Future studies will enhance our understanding
of the underlying mechanism and role of Imp1–3 in onco-
genic networks.
Materials and methods
All sequencing data are available in the NCBI sequence reposito-
ry under accession number PRJNA383556.
Cell culture
MSCs were cultured at 37°C with 5% CO2 in α-MEM supple-
mented with 100 U/mL penicillin, 100 μg/mL streptomycin,
and 10% fetal bovine serum.
Protein analysis
Cells were harvested in RIPA supplemented with protease inhib-
itor cocktail (Roche), and samples were diluted in Laemilli buffer
with DTT. Samples were electrophoresed using the Nu-PAGE
Bis-Tris electrophoresis system (Life Technologies) as per the
manufacturer’s instructions and transferred to a polyvinylidene
fluoride (PVDF) or nitrocellulose membrane in a Mini Trans-
Blot wet transfer apparatus (Bio-Rad). Membranes were blocked
in 5%milk in TBST (for ECL-based detection) or Odyssey block-
ing buffer (for Licor-based detection). Primary antibody incuba-
tion was performed overnight, and samples were detected on
filmusing ECL (Perkin Elmer) or visualized usingOdyssey (Licor).
The Imp1–3 polyclonal antibodies were obtained fromMBL In-
ternational (catalog nos. RN007P, RN008P, and RN009P), anti-
Hmga2 was ofrom Cell Signaling (catalog no. 5269), anti-p107
and anti-Actin were from Santa Cruz Biotechnology (catalog
nos. sc-318 and sc-130656), anti-HA and anti-vinculin were
from Sigma-Aldrich (catalog nos. 11867423001 and V9131), and
anti-Dicer was fromBethyl Laboratories (catalog no. A301-936A).
qPCR
Total RNAwas isolated using Trizol or the RNeasy minikit (Qia-
gen) following the manufacturer’s instructions, treated with the
Turbo DNA-free kit (Life Technologies), and reverse-transcribed
with oligo(dT) primers using SuperScript III (Life Technologies).
qPCR reactions on resulting cDNAswere performed using Power
SYBR Green (Life Technologies) run on an Applied Biosystems
7500 real-time PCR instrument. qPCR primers are listed in Sup-
plemental Table S7.
Northern blot
Total RNAwas separated on a 12% polyacrylamide/urea/TBE gel
(Sequagel, National Diagnostics) and transferred to a HyBond N+
membrane (GE Healthcare) using the TransBlot SD semidry
transfer system (Bio-Rad). RNA was then UV cross-linked to the
membrane. DNA oligo probes perfectly complementary to the
miRNAs of interest were γ-32P end-labeled using T4 polynucleo-
tide kinase (NewEngland Biolabs) and purified using IllustraG-25
MicroSpin columns (GE Healthcare). Membranes were prehybri-
dized in UltraHyb oligo (Ambion) for at least 30 min at 42°C and
then hybridized with a radiolabeled DNA probe overnight at
42°C. Blots were washed twice for 30 min with 2× SSC and
0.5% SDS prewarmed to 42°C. RNA was visualized by exposure
to phosphor screens and then imaged on a Storm scanner (Molec-
ular Dynamics).
Animal work
All animal work was performed under the guidelines of the Mas-
sachusetts Institute of Technology (MIT) Division of Compara-
tive Medicine with protocols approved by the MIT Committee
for Animal Care and were consistent with the Guide for the
Care andUse of Laboratory Animals, National Research Council,
1996 (Institutional Animal Welfare Assurance no. A-3125-01).
Soft agar assay
Cells were suspended in 0.4% SeaPlaque agarose (Lonza) in com-
plete DMEMand seeded over a first layer of 0.8% agarose in com-
plete DMEM. Cells were seeded using 2 × 104 to 4 × 104 cells per
well of a six-well plate and in triplicate for each cell type. Cells
were grown at 37°C and 5% CO2, and colonies were counted 2–
3wk after seeding. For each replicate, five random fieldswere cap-
tured by light microscopy at 4× magnification, and the number of
colonies in each field was counted manually by eye.
GILA
Subconfluent cells were trypsinized, counted, and seeded at 1000
cells per well of a 96-well plate in 100 µL of cell culture medium
on ultralow-attachment round-bottom plates (Corning, catalog
no. 7007). Cells were cultured at 37°C with 5% CO2, and, at the
respective time points, plates were transferred to −80°C in order
to freeze the cell suspension. At the completion of the time course,
cells were assayed for ATP content as a proxy of cell viability using
the CellTiter-Glo luminescent cell viability assay (Promega)
according to the previously described protocol (Rotem et al. 2015).
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